Roivant Sciences (ROIV) Receivables (2021 - 2024)
Roivant Sciences' (ROIV) quarterly Receivables came in at $678000.0 in Q4 2024, down 98.35% YoY from $41.1 million in Q1 2024, and down 64.61% on a QoQ basis from $1.9 million in Q3 2024.
Roivant Sciences (ROIV) Receivables (2021 - 2024) Analysis & Trends
Roivant Sciences (ROIV) has 4 years of Receivables data on file, last reported at $678000.0 in Q4 2024.
- Quarterly Receivables fell 98.35% year-over-year to $678000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $678000.0 (down 98.35% YoY) and the FY2024 annual result came in at $678000.0, down 98.35% from the prior year.
- Receivables retreated to $678000.0 in Q4 2024, from $1.9 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $79.8 million in Q2 2024 to a low of $678000.0 in Q4 2024.
- A 4-year average of $22.5 million and a median of $11.2 million in 2021 frame the typical range for Receivables.
- Annual changes were most pronounced in 2023 — Receivables jumped 683.37% — and 2024, when it slumped 98.35%.
- Tracing ROIV's Receivables over 4 years: stood at $8.9 million in 2021, then surged by 213.5% to $28.0 million in 2022, then surged by 46.88% to $41.1 million in 2023, then tumbled by 98.35% to $678000.0 in 2024.
- The last three Receivables figures came in at $678000.0 (Q4 2024), $1.9 million (Q3 2024), and $79.8 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 678,000.00 |
| Sep 30, 2024 | 1.92 Mn |
| Jun 30, 2024 | 79.79 Mn |
| Mar 31, 2024 | 3.99 Mn |
| Dec 31, 2023 | 41.08 Mn |
| Sep 30, 2023 | 52.12 Mn |
| Jun 30, 2023 | 37.06 Mn |
| Mar 31, 2023 | 30.38 Mn |
| Dec 31, 2022 | 27.97 Mn |
| Sep 30, 2022 | 25.04 Mn |
| Mar 31, 2022 | 3.88 Mn |
| Dec 31, 2021 | 8.92 Mn |
| Sep 30, 2021 | 9.81 Mn |
| Jun 30, 2021 | 3.42 Mn |
| Mar 31, 2021 | 11.22 Mn |